ANTIVIRAL THERAPY FOR HERPES SIMPLEX VIRUS ENCEPHALITIS: SYSTEMATIC REVIEW

Authors

  • Agnes Annurul Maulidia Faculty of Medicine, Bandung Islamic University, Indonesia
  • Media Yuni Kurniawati Cibabat General Hospital, Indonesia

DOI:

https://doi.org/10.53555/nnmhs.v9i8.1818

Keywords:

Acyclovir, Antiviral therapy, Encephalitis, Herpes simplex virus, Valacyclovir

Abstract

Introduction: Without regard to treatment, herpes simplex encephalitis is detrimental. Neonatal encephalitis caused by HSV-2 affects the brain more extensively, resulting in more neurologic complications. Viral variables and host immune responses determine virulence and invasiveness in adults. In order to maintain latency, it is necessary to inhibit viral lytic-phase genes and modify innate and adaptive immune responses to thwart host cellular defenses.

The aim: This article explore effectiveness and safety antiviral therapy for herpes simplex virus encephalitis.

Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.

Result: In the PubMed database, the results of our search brought up 67 articles, whereas the results of our search on SagePub brought up 53 articles. The results of the search conducted for the last year of 2010 yielded a total 11 articles for PubMed and 3 articles for SagePub. In the end, we compiled a total of 8 papers, 7 of which came from PubMed and one of which came from SagePub. We included two research that met the criteria.

Conclusion: The standard treatment of HSV-1 encephalitis is IV acyclovir, as PO acyclovir and valacyclovir require multiple doses per day.

References

. Clebak KT, Malone MA. Skin Infections. Prim Care. 2018 Sep;45(3):433–54.

. Widener RW, Whitley RJ. Herpes simplex virus. In: Handbook of clinical neurology. Elsevier; 2014. p. 251–63.

. Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9):760–72.

. Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herpes simplex virus infections. J Neurovirol. 2013;19:328–45.

. Whitley R, Baines J. Clinical management of herpes simplex virus infections: past, present, and future. F1000Research. 2018;7.

. Gnann JW, Whitley RJ. Herpes simplex encephalitis: an update. Curr Infect Dis Rep. 2017;19:1–12.

. James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ, Gottlieb SL, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020;98(5):315.

. Kennedy PGE, Steiner I. Recent issues in herpes simplex encephalitis. J Neurovirol. 2013;19:346–50.

. Safain MG, Roguski M, Kryzanski JT, Weller SJ. A review of the combined medical and surgical management in patients with herpes simplex encephalitis. Clin Neurol Neurosurg. 2015;128:10–6.

. Gnann Jr JW, Sköldenberg B, Hart J, Aurelius E, Schliamser S, Studahl M, et al. Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy. Clin Infect Dis. 2015;61(5):683–91.

Downloads

Published

2023-08-21

How to Cite

Annurul Maulidia, A. ., & Yuni Kurniawati, M. . (2023). ANTIVIRAL THERAPY FOR HERPES SIMPLEX VIRUS ENCEPHALITIS: SYSTEMATIC REVIEW. Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425), 9(8), 178-183. https://doi.org/10.53555/nnmhs.v9i8.1818